Regeneron Pharmaceuticals, Inc. (REGN)
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
Regeneron is an innovative drugmaker that continues to perform well. Shopify's changed and improved business should lead to stronger returns.
Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 11:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations and Strategic Analysis Chris Fenimore - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Thanks for joining us, everybody.
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
Regeneron Stock: Valuation Now Demands More Growth
Regeneron Pharmaceuticals stock reached new all-time highs this month, driven by the Eylea franchise returning to growth in the second quarter, and despite minor regulatory setbacks for the oncology pipeline. Dupixent and Libtayo delivered strong growth in the second quarter. European Commission approvals of Dupixent for COPD and odronextamab for two hematologic malignancies offer some consolation after FDA delays and rejections for the same applications.
Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug
Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.
US FDA declines to approve Regeneron's blood cancer therapy
The U.S. Food and Drug Administration declined to approve Regeneron's therapy for a common form of blood cancer, the company said on Tuesday.
2 Biotech Stocks To Watch In August 2024
Biotech stocks to keep on your radar this month.
Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent
Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.
Is Regeneron Pharmaceuticals Due for a Stock Split?
Regeneron shares have recently crossed over the $1,000 price point. The company has achieved significant growth and there could more to come.
Regeneron's Robust Pipeline And Financial Health Signal Continued Growth
Regeneron's Q2 2024 revenue grew 12% year-over-year, reaching $3.55 billion. Dupixent's global net sales increased by 27% to $3.56 billion, driving overall revenue growth. Eylea HD mitigated market share losses by earning $304 million and stabilizing the Eylea franchise.
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2024 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations and Strategic Analysis Leonard Schleifer - Board Co-Chair, Co-Founder, President and Chief Executive Officer George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - Executive Vice President, Commercial Chris Fenimore - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Evan Seigerman - BMO Capital Markets Brian Abrahams - RBC Capital Markets Cory Kasimov - Evercore ISI Christopher Raymond - Piper Sandler Katherine Wang - Jefferies Chris Schott - JPMorgan Tim Anderson - Wolfe Research David Risinger - Leerink Partners Salveen Richter - Goldman Sachs Carter Gould - Barclays Mohit Bansal - Wells Fargo Operator Welcome to the Regeneron Pharmaceuticals Second Quarter 2024 Earnings Conference Call. My name is Shannon and I will be your operator for today's call.
Compared to Estimates, Regeneron (REGN) Q2 Earnings: A Look at Key Metrics
The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
